A phase I randomized, <scp>double‐blind</scp> , single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects

Kenan Gu, Dennis Ruff, Cassandra Key, Marissa Thompson, Shoshanna Jiang, Taylor Sandison, Shawn Flanagan

Open source

DOI: 10.1111/cts.13286
Published: 2022-05-04
Container: Clinical and Translational Science
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/cts.13286,
  title = {A phase I randomized,
                    <scp>double‐blind</scp>
                    , single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects},
  author = {Kenan Gu and Dennis Ruff and Cassandra Key and Marissa Thompson and Shoshanna Jiang and Taylor Sandison and Shawn Flanagan},
  year = {2022},
  journal = {Clinical and Translational Science},
  doi = {10.1111/cts.13286},
  url = {https://doi.org/10.1111/cts.13286}
}

RIS

TY  - JOUR
TI  - A phase I randomized,
                    <scp>double‐blind</scp>
                    , single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects
AU  - Kenan Gu
AU  - Dennis Ruff
AU  - Cassandra Key
AU  - Marissa Thompson
AU  - Shoshanna Jiang
AU  - Taylor Sandison
AU  - Shawn Flanagan
PY  - 2022
JO  - Clinical and Translational Science
DO  - 10.1111/cts.13286
UR  - https://doi.org/10.1111/cts.13286
ER  -

APA

Gu, K., Ruff, D., Key, C., Thompson, M., Jiang, S., Sandison, T., & Flanagan, S. (2022). A phase I randomized, <scp>double‐blind</scp> , single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects. Clinical and Translational Science. https://doi.org/10.1111/cts.13286

Source records

crossref · retrieved 2026-09-24T22:42:57.367Z